CRISPR Therapeutics AG is a biotechnology company. The company researches, develops and produces biologically transmutable genetics and other related products. CRISPR Therapeutics operates in Switzerland.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential
CRISPR Therapeutics news
10.05.2022
CRISPR Therapeutics' GAAP loss for 3 months of 2022 was $179.217 million, up 58.4% from $113.163 million in the prior year. Revenue increased 74.4% to $940 million from $539 million a year earlier.
Source: 
ir.crisprtx.com
ir.crisprtx.com
16.02.2022
CRISPR Therapeutics' GAAP net income for 2021 was $377.661 million, compared to a loss of $348.865 million the previous year. Revenue increased multiple times to $914.963 million from $0.719 million a year earlier.
Source: ir.crisprtx.com
ir.crisprtx.com
05.11.2021
CRISPR Therapeutics' GAAP net income for 9M 2021 was $218.909 million, against a loss of $241.826 million in the previous year. Revenue increased multiple times to $902.064 million from $0.349 million a year earlier.
Source: ir.crisprtx.com
ir.crisprtx.com
30.07.2021
CRISPR Therapeutics' GAAP net income for 6 months of 2021 was $646.062 million, compared to a loss of $149.387 million in the previous year. Revenue increased multiple times to $901.24 million from $0.201 million a year earlier.
Source: ir.crisprtx.com
ir.crisprtx.com
General information
| Company name | CRISPR Therapeutics |
|---|---|
| Tags | #biotechnology |
| Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology |
| Business address | BAARERSTRASSE 14 ZUG V8 CH-6300 6173154600 |
| Mailing address | BAARERSTRASSE 14 ZUG V8 CH-6300 |
| Website | www.crisprtx.com |
| Information disclosure | www.sec.gov |
English (US) 